Hojjat Ahmadzadehfar
University Hospital Bonn
CancerInternal medicineRadiologyPET-CTSurgeryPathologyOncologyAdverse effectPositron emission tomographyHepatocellular carcinomaProgressive diseaseNeuroendocrine tumorsProstate cancerNuclear medicineRadionuclide therapyPeptide receptorIn patientRadioligandMedicineGastroenterology
242Publications
36H-index
4,539Citations
Publications 244
Newest
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive. Combined treatments anticipate synergistic effects and thus better responses by combining ionizing radiation with other anti-tumor treatments. Furthermore, multimodal therapies often have a balanced toxicity profile. To date, few studies have evaluated the effect of combination therapies with PRRT, some of them phase I/II trials. ...
Source
#1H. PalmedoH-Index: 2
Last. Felix M. MottaghyH-Index: 72
view all 14 authors...
Source
#1Majid AssadiH-Index: 20
Last. Narges JokarH-Index: 2
view all 12 authors...
Introduction null Fibroblast activation protein (FAP) is a member of the serine protease family and has a high expression in the stroma of approximately 90% of epithelial malignancies. The present investigation aimed to assess the feasibility, safety, and dosimetry data of 177Lu-FAPI-46 in diverse malignancies. null Patients and methods null Patients with advanced cancers with nonoperable tumors, or tumors refractory to conventional therapies, were enrolled. Treatment included escalating doses o...
Source
#1Majid Assadi (Bushehr University of Medical Sciences)H-Index: 20
#2Narges Jokar (Bushehr University of Medical Sciences)H-Index: 2
Last. Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
view all 10 authors...
Studies in nuclear medicine have shed light on molecular imaging and therapeutic approaches for oncological and nononcological conditions. Using the same radiopharmaceuticals for diagnosis and therapeutics of malignancies, the theranostics approach, has improved clinical management of patients. Theranostic approaches for nononcological conditions are recognized as emerging topics of research. This review focuses on preclinical and clinical studies of nononcological disorders that include therano...
Source
#1Hossein Shooli (Bushehr University of Medical Sciences)H-Index: 2
#2Reza Nemati (Bushehr University of Medical Sciences)H-Index: 10
Last. Majid Assadi (Bushehr University of Medical Sciences)H-Index: 20
view all 11 authors...
Theranostic nuclear oncology, mainly in neuro-oncology (neurotheranostics), aims to combine cancer imaging and therapy using the same targeting molecule. This approach tries to identify patients who are most likely to benefit from tumor molecular radionuclide therapy. The ability of radioneurotheranostic agents to interact with cancer cells at the molecular level with high specificity can significantly improve the effectiveness of cancer therapy. A variety of biologic targets are under investiga...
Source
Source
#1Nasim Vahidfar (Tehran University of Medical Sciences)H-Index: 3
#2Elisabeth EppardH-Index: 9
Last. Hojjat AhmadzadehfarH-Index: 36
view all 6 authors...
Radiometal-based theranostics or theragnostics, first used in the early 2000s, is the combined application of diagnostic and therapeutic agents that target the same molecule, and represents a considerable advancement in nuclear medicine. One of the promising fields related to theranostics is radioligand therapy. For instance, the concepts of targeting the prostate-specific membrane antigen (PSMA) for imaging and therapy in prostate cancer, or somatostatin receptor targeted imaging and therapy in...
1 CitationsSource
#1Farzaneh Ghaderi (Bushehr University of Medical Sciences)
#2Narges Jokar (Bushehr University of Medical Sciences)H-Index: 2
Last. Hojjat AhmadzadehfarH-Index: 36
view all 5 authors...
This review aims to focus on cancer stem cell (CSC) development and properties, and highlight some of the possible methods of targeting CSCs including surface markers, signalling pathways in cancer stem cells, and recently introduced theranostics approach to accomplish better treatment results in cancer therapy. A literature search was performed using the PubMed/MEDLINE and Clinical Trials.gov database and “CSC”, “cancer-stem-cell”, “mi-RNA”, “signalling pathway”, “CSC-specific cell surface mark...
Source
#1Majid Assadi (Bushehr University of Medical Sciences)H-Index: 20
#2Seyed Javad Rekabpour (Bushehr University of Medical Sciences)H-Index: 3
Last. Hojjat AhmadzadehfarH-Index: 36
view all 9 authors...
We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.
1 CitationsSource
#1Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
#2Ralf Matern (University Hospital Bonn)H-Index: 1
Last. Kambiz RahbarH-Index: 22
view all 19 authors...
INTRODUCTION Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement. METHODS The study incl...
2 CitationsSource